Search - tctmd.com

Displaying 61 - 80 of 117

Sort: Relevancy | Date

News Daily News

Who Should Head to the Cath Lab in the COVID-19 Pandemic?

Michael O'Riordan

March 26, 2020

News Features

Trial by Twitter: How a 280-Character Count Is Reshaping Cardiology

Michael O'Riordan

March 03, 2020

News Daily News

BBC Makes New EXCEL Allegations, Says Investigators Ignored Safety Concerns

Michael O'Riordan

February 21, 2020

News Features

Year in Review: ISCHEMIA Tops Coronary News in 2019 but Other Trials Shine, Too

Michael O'Riordan

December 09, 2019

News Conference News VIVA 2019

Nearly 1 Year Later, Endovascular Community Continues to Struggle With Paclitaxel

L.A. McKeown

November 08, 2019

News Daily News

Repeat Target-Lesion PCI: An Option for Public Reporting?

Michael O'Riordan

October 25, 2019

News Daily News

Recurrent Events Common Among Young Patients With CAD

Michael O'Riordan

October 11, 2019

News Conference News

Former EXCEL Investigator Alleges Trial Manipulation, Prompting Vehement Denials

Michael O'Riordan

October 07, 2019

News Daily News

CMS Weighs Reimbursement for Out-of-Hospital Coronary Interventions

Caitlin E. Cox

September 20, 2019

News Daily News

FDA Panel Talks Labeling, Urges Cooperation for Paclitaxel Mortality Signal in PAD

L.A. McKeown

June 20, 2019

News Daily News

FDA Advisors Face ‘Forest of Dueling Numbers’ at Paclitaxel PAD Device Review: Day One

L.A. McKeown

June 19, 2019

News Industry News

Concept Medical Inc. Granted "Breakthrough Device Designation" From FDA for Its MagicTouch Sirolimus Coated Balloon

May 02, 2019

News Daily News

Does PCI Public Reporting Affect Angiography for Out-of-Hospital Cardiac Arrest?

Michael O'Riordan

April 11, 2019

News Daily News

Race, Socioeconomic Status Gaps in Revascularization Rates Persist Among Women With ACS

Yael L. Maxwell

April 05, 2019

News Opinion Fellow Talk

Public Reporting and the Budding Interventional Cardiologist

Yashasvi Chugh, MD

March 28, 2019

Time and Money: PCI Public Reporting Requirements Takes Their Toll

News Conference News ACC 2019

Time and Money: PCI Public Reporting Requirements Take Their Toll

Michael O'Riordan

March 26, 2019

News Conference News CRT 2019

Acknowledgment of Safety Signal for Paclitaxel Devices in PAD May Mark Sea Change in Controversy

L.A. McKeown

March 06, 2019

News Daily News

ISCHEMIA Patients: High Rates of Severe-to-Moderate Ischemia, Multivessel CAD

Michael O'Riordan

March 01, 2019

News Daily News

IN.PACT Admiral Data Show No Death Difference at 5 Years for Paclitaxel DCBs vs PTA in Femoropopliteal Disease

L.A. McKeown

January 25, 2019

News Daily News

Industry, Investigators Push Back With Patient-Level Data Showing No Increased Death From Paclitaxel-Based PAD Therapies

L.A. McKeown

January 23, 2019

Advertisement

Who Should Head to the Cath Lab in the COVID-19 Pandemic?

Trial by Twitter: How a 280-Character Count Is Reshaping Cardiology

BBC Makes New EXCEL Allegations, Says Investigators Ignored Safety Concerns

Year in Review: ISCHEMIA Tops Coronary News in 2019 but Other Trials Shine, Too

Nearly 1 Year Later, Endovascular Community Continues to Struggle With Paclitaxel

Repeat Target-Lesion PCI: An Option for Public Reporting?

Recurrent Events Common Among Young Patients With CAD

Former EXCEL Investigator Alleges Trial Manipulation, Prompting Vehement Denials

CMS Weighs Reimbursement for Out-of-Hospital Coronary Interventions

FDA Panel Talks Labeling, Urges Cooperation for Paclitaxel Mortality Signal in PAD

FDA Advisors Face ‘Forest of Dueling Numbers’ at Paclitaxel PAD Device Review: Day One

Concept Medical Inc. Granted "Breakthrough Device Designation" From FDA for Its MagicTouch Sirolimus Coated Balloon

Does PCI Public Reporting Affect Angiography for Out-of-Hospital Cardiac Arrest?

Race, Socioeconomic Status Gaps in Revascularization Rates Persist Among Women With ACS

Public Reporting and the Budding Interventional Cardiologist

Time and Money: PCI Public Reporting Requirements Take Their Toll

Acknowledgment of Safety Signal for Paclitaxel Devices in PAD May Mark Sea Change in Controversy

ISCHEMIA Patients: High Rates of Severe-to-Moderate Ischemia, Multivessel CAD

IN.PACT Admiral Data Show No Death Difference at 5 Years for Paclitaxel DCBs vs PTA in Femoropopliteal Disease

Industry, Investigators Push Back With Patient-Level Data Showing No Increased Death From Paclitaxel-Based PAD Therapies

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content